Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K Antagonists
Introduction: Nephrotic syndrome (NS) is a pathological state of the glomerular filtration barrier associated with an increased venous and arterial thrombotic risk. Current guidelines suggest heparin-based or vitamin K antagonist (VKA) regimens for thromboprophylaxis in such patients. Although widel...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024925001184 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849335955335413760 |
|---|---|
| author | Edouard Cubilier Youcef Chergui Cyril Garrouste Ines Ramos Carole Philipponnet Alba Atenza Clarisse Greze Julien Aniort Charlotte Uro-Coste Anne-Elisabeth Heng |
| author_facet | Edouard Cubilier Youcef Chergui Cyril Garrouste Ines Ramos Carole Philipponnet Alba Atenza Clarisse Greze Julien Aniort Charlotte Uro-Coste Anne-Elisabeth Heng |
| author_sort | Edouard Cubilier |
| collection | DOAJ |
| description | Introduction: Nephrotic syndrome (NS) is a pathological state of the glomerular filtration barrier associated with an increased venous and arterial thrombotic risk. Current guidelines suggest heparin-based or vitamin K antagonist (VKA) regimens for thromboprophylaxis in such patients. Although widely prescribed for other indications, direct oral anticoagulants (DOACs) are not recommended in NS because of limited pharmacological and safety reports. This study aimed to compare DOACs and VKAs for thromboprophylaxis in NS, specifically regarding thrombotic events (TEs) and bleeding events (BEs). Methods: We conducted a retrospective monocentric analysis of recorded NS episodes that required prophylactic anticoagulation between January 2006 and December 2023. We included 133 NS episodes of which 51 were treated with DOACs and 82 with VKAs. The primary endpoint was a composite endpoint, including thrombosis occurrence and major or clinically significant BEs during thromboprophylaxis. The secondary endpoints consisted of relevant features potentially involved when each primary endpoint was considered independently. Results: Patient characteristics, underlying NS etiology, personal thrombotic and bleeding risk factors, and biological parameters were globally similar in both groups. The primary endpoint appeared similar in both groups (P = 0.481). The secondary endpoints were mostly hypothesis-generating because of the low TE (n = 2) and BE (n = 7) occurrences. Conclusion: This study provides reassuring clinical data on DOAC use in NS thromboprophylaxis compared with VKAs, the recommended therapy, and calls for confirmation in randomized controlled trials (RCTs) and larger pharmacological studies. |
| format | Article |
| id | doaj-art-fd6252b2864a4e1e88f1fc2048393826 |
| institution | Kabale University |
| issn | 2468-0249 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney International Reports |
| spelling | doaj-art-fd6252b2864a4e1e88f1fc20483938262025-08-20T03:45:07ZengElsevierKidney International Reports2468-02492025-05-011051468147510.1016/j.ekir.2025.02.028Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K AntagonistsEdouard Cubilier0Youcef Chergui1Cyril Garrouste2Ines Ramos3Carole Philipponnet4Alba Atenza5Clarisse Greze6Julien Aniort7Charlotte Uro-Coste8Anne-Elisabeth Heng9Nephrology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France; Correspondence: Edouard Cubilier, Nephrology Department, University Hospital of Clermont-Ferrand, Gabriel-Montpied site, 58 Montalembert Street, Clermont-Ferrand, France.Nephrology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, FranceNephrology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, FranceBiostatistics Unit, DRCI, Clermont-Ferrand University Hospital, Clermont-Ferrand, FranceNephrology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, FranceNephrology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, FranceNephrology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, FranceNephrology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, FranceNephrology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, FranceNephrology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, FranceIntroduction: Nephrotic syndrome (NS) is a pathological state of the glomerular filtration barrier associated with an increased venous and arterial thrombotic risk. Current guidelines suggest heparin-based or vitamin K antagonist (VKA) regimens for thromboprophylaxis in such patients. Although widely prescribed for other indications, direct oral anticoagulants (DOACs) are not recommended in NS because of limited pharmacological and safety reports. This study aimed to compare DOACs and VKAs for thromboprophylaxis in NS, specifically regarding thrombotic events (TEs) and bleeding events (BEs). Methods: We conducted a retrospective monocentric analysis of recorded NS episodes that required prophylactic anticoagulation between January 2006 and December 2023. We included 133 NS episodes of which 51 were treated with DOACs and 82 with VKAs. The primary endpoint was a composite endpoint, including thrombosis occurrence and major or clinically significant BEs during thromboprophylaxis. The secondary endpoints consisted of relevant features potentially involved when each primary endpoint was considered independently. Results: Patient characteristics, underlying NS etiology, personal thrombotic and bleeding risk factors, and biological parameters were globally similar in both groups. The primary endpoint appeared similar in both groups (P = 0.481). The secondary endpoints were mostly hypothesis-generating because of the low TE (n = 2) and BE (n = 7) occurrences. Conclusion: This study provides reassuring clinical data on DOAC use in NS thromboprophylaxis compared with VKAs, the recommended therapy, and calls for confirmation in randomized controlled trials (RCTs) and larger pharmacological studies.http://www.sciencedirect.com/science/article/pii/S2468024925001184direct oral anticoagulantnephrotic syndromethromboprophylaxisvitamin K antagonist |
| spellingShingle | Edouard Cubilier Youcef Chergui Cyril Garrouste Ines Ramos Carole Philipponnet Alba Atenza Clarisse Greze Julien Aniort Charlotte Uro-Coste Anne-Elisabeth Heng Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K Antagonists Kidney International Reports direct oral anticoagulant nephrotic syndrome thromboprophylaxis vitamin K antagonist |
| title | Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K Antagonists |
| title_full | Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K Antagonists |
| title_fullStr | Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K Antagonists |
| title_full_unstemmed | Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K Antagonists |
| title_short | Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K Antagonists |
| title_sort | nephrotic syndrome thromboprophylaxis with direct oral anticoagulants or vitamin k antagonists |
| topic | direct oral anticoagulant nephrotic syndrome thromboprophylaxis vitamin K antagonist |
| url | http://www.sciencedirect.com/science/article/pii/S2468024925001184 |
| work_keys_str_mv | AT edouardcubilier nephroticsyndromethromboprophylaxiswithdirectoralanticoagulantsorvitaminkantagonists AT youcefchergui nephroticsyndromethromboprophylaxiswithdirectoralanticoagulantsorvitaminkantagonists AT cyrilgarrouste nephroticsyndromethromboprophylaxiswithdirectoralanticoagulantsorvitaminkantagonists AT inesramos nephroticsyndromethromboprophylaxiswithdirectoralanticoagulantsorvitaminkantagonists AT carolephilipponnet nephroticsyndromethromboprophylaxiswithdirectoralanticoagulantsorvitaminkantagonists AT albaatenza nephroticsyndromethromboprophylaxiswithdirectoralanticoagulantsorvitaminkantagonists AT clarissegreze nephroticsyndromethromboprophylaxiswithdirectoralanticoagulantsorvitaminkantagonists AT julienaniort nephroticsyndromethromboprophylaxiswithdirectoralanticoagulantsorvitaminkantagonists AT charlotteurocoste nephroticsyndromethromboprophylaxiswithdirectoralanticoagulantsorvitaminkantagonists AT anneelisabethheng nephroticsyndromethromboprophylaxiswithdirectoralanticoagulantsorvitaminkantagonists |